newsfilter
← Latest News
GlobeNewswire·

UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease

In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical